小细胞肺癌中的免疫异质性以及对免疫检查点阻塞的脆弱性
Barzin Y Nabet1, Habib Hamidi1, Myung Chang Lee1
1Genentech Inc., South San Francisco CA, USA.
Cancer cell
|February 17, 2024
概括
研究人员确定了四种扩散阶段小细胞肺癌 (ES-SCLC) 的亚型. 具有高T效应信号的神经内分泌瘤显示,阿特佐利祖马布 (抗PD-L1) 和化疗改善了生存率,指导免疫疗法策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 阿特佐利祖马布 (抗PD-L1) 加上卡博普拉丁和埃托 (CE) 是扩散阶段小细胞肺癌 (ES-SCLC) 的标准治疗方法.
- 识别特定的SCLC子集可以优化组合疗法和患者的治疗结果.
研究的目的:
- 通过转录基因分析将ES-SCLC患者分为治疗相关的亚型.
- 调查SCLC内的免疫异质性及其与免疫治疗反应的相关性.
主要方法:
- 对IMpower133试验的271个治疗前ES-SCLC瘤样本进行了转录组分析和非负矩阵因子化.
- 根据基因表达特征和免疫细胞透模式,确定和描述了亚型.
主要成果:
- 确定了四个SCLC子集 (SCLC-A, -N, -P, -I),基本上与已知的亚型一致.
- 两种不同的免疫表型出现了:神经内分泌 (NE) 瘤具有较低的瘤相关巨细胞 (TAM) 和高的T-效应信号,以及具有高TAM和高T-效应信号的非NE瘤.
- 具有高T效应信号的NE瘤在与单独CE相比,在接受阿特佐利祖马布加CE治疗时,总体存活时间显着更长.
结论:
- 这项研究提供了一个临床相关的框架,用于基于转录和免疫特征的ES-SCLC患者的分层.
- 了解SCLC免疫异质性对于预测PD-L1阻塞与化疗相结合的反应至关重要.
相关概念视频
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K


